ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1954

Revolutionizing Microvascular Screening: AI-Powered Dermatoscopy for Efficient Nailfold Capillary Evaluation

Genessis Maldonado1, Eduardo Ramos ibáñez2, Borja del Carmelo Gracia Tello3 and Tracy Frech4, 1Vanderbilt University Medical Center, Nashville, 2Capillary.io, Zaragoza, Aragon, Spain, 3Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 4Vanderbilt University Medical Center, Nashville, TN

Meeting: ACR Convergence 2025

Keywords: Imaging, Raynaud's phenomenon, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1936–1971) Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Nailfold capillaroscopy plays a critical role in the diagnosis and management of systemic sclerosis (SSc) and related connective tissue diseases. However, access to capillaroscopy remains limited outside specialized rheumatology centers. Dermatoscopy is a more accessible alternative, but its use for nailfold evaluation lacks standardization. In 2024, we demonstrated preliminary evidence that artificial intelligence (AI) could support dermatoscopic nailfold analysis in rheumatology clinics (Maldonado et al., Arthritis Rheumatol. 2024). Building on that work, we now present a refined and more efficient AI model designed for possible real-world implementation.

Methods: We developed a multi-label image classification model using 1,405 dermatoscopic nailfold images labeled for five key features: abnormal shapes, giant capillaries (replacing the broader “enlarged” category for better dermatoscopic specificity), hemorrhages, low capillary density, and image blurriness. Unlike our 2024 approach, which used separate binary models per feature, this year’s model employs a unified architecture to predict all labels simultaneously—enhancing computational efficiency and deployment feasibility. The model was based on ConvNeXt V2 and trained on an 80/20 stratified split, with performance evaluated using standard machine learning metrics. Images were retrieved using a 200x magnification lens adapted for smartphones (value $30).

Results: The model achieved strong performance across all target features (table 1), with F1-scores as follows: abnormal shapes (0.643), giant capillaries (0.647), hemorrhages (0.649), low density (0.667), and image too blurry (0.874), yielding a mean F1-score of 0.696. The multi-label framework significantly reduced inference time and memory usage while maintaining consistent accuracy across folds (table 2). The model also demonstrated robustness despite the lower resolution typical of dermatoscopic images compared to nailfold capillaroscopy.

Conclusion: This AI-driven model shows promising accuracy in detecting microvascular abnormalities from dermatoscopic images and represents a meaningful step toward accessible, point-of-care screening for SSc and related diseases. By leveraging the lightweight ConvNeXt V2 architecture in a multi-label framework, we pave the way for integration into mobile applications using a smartphone camera and dermatoscopy lens. Such a tool could support early detection of microvascular abnormalities in patients with Raynaud’s phenomenon, especially in non-specialist or resource-limited settings. However, given the high proportion of low-quality (blurry) images in dermatoscopy and in alignment with current recommendations (Mislav R. et al. Clin Exp Rheumatol. 2020;38 Suppl 125:132–136), nailfold video capillaroscopy should be pursued for comprehensive evaluation when clinically indicated. Prospective validation and clinical integration studies are ongoing.

Supporting image 1Table 1. Model performance

Supporting image 2Table 2. Sample of images by label.


Disclosures: G. Maldonado: None; E. Ramos ibáñez: None; B. Gracia Tello: None; T. Frech: None.

To cite this abstract in AMA style:

Maldonado G, Ramos ibáñez E, Gracia Tello B, Frech T. Revolutionizing Microvascular Screening: AI-Powered Dermatoscopy for Efficient Nailfold Capillary Evaluation [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/revolutionizing-microvascular-screening-ai-powered-dermatoscopy-for-efficient-nailfold-capillary-evaluation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/revolutionizing-microvascular-screening-ai-powered-dermatoscopy-for-efficient-nailfold-capillary-evaluation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology